Table 2.

Association of expanded set of candidate single nucleotide polymorphisms with blood pressure phenotypes

Index SNP	Chr	Position	Genes	WGHS							ICBP
				A1/A2	A1F	Genotype	BP phenotype	Beta (SE)	P valuea	Empirical P valueb	P value
Nominal significant associations in the WGHS
rs1507023	16	7528435	RBFOX1	G/A	0.13	Genotyped	SBP	0.55 (0.28)	0.05	0.90	0.14
							PP	0.43 (0.16)	0.0078	0.31
rs2296241	20	52219626	CYP24A1	G/A	0.47	Imputed	SBP	0.42 (0.19)	0.023	0.67	0.08
							DBP	0.28 (0.12)	0.024	0.68	0.11
							MAP	0.32 (0.14)	0.022	0.64
Nominal significant associations in the ICBP
rs2853564	12	46564753	VDR	G/A	0.40	Genotyped	SBP	−0.069 (0.19)	0.72	1.00	0.045
rs1507023	16	7528435	RBFOX1	G/A	0.13	Genotyped	DBP	0.23 (0.18)	0.21	1.00	0.04
rs9937918	16	56159292	GPR114	A/G	0.27	Genotyped	SBP	0.22 (0.21)	0.30	1.00	0.02
							DBP	0.12 (0.14)	0.40	1.00	0.049
rs6013897	20	52175886	CYP24A1	A/T	0.21	Imputed	SBP	0.023 (0.23)	0.92	1.00	0.045
							DBP	−0.0081 (0.15)	0.96	1.00	0.02

Candidate single nucleotide polymorphisms (SNPs) included those that have previously shown significant associations with blood pressure (BP)–related outcomes, vitamin D metabolism, or vitamin D receptor signaling. Table only shows SNPs that had significant association with any BP phenotype at nominal P < 0.05 in the Women’s Genome Health Study (WGHS) or International Consortium of Blood Pressure (ICBP). In the WGHS, analysis was adjusted for age at randomization and population stratification; data presented are effect size beta (SE) in millimeters of mercury per coded allele; all imputation r ² > 0.80. In the ICBP, P for SNP presented are genome-wide meta-analysis P values after correction for genomic control.

Abbreviations: A1, coded allele; A2, noncoded allele; A1F, coded allele frequency; Chr, chromosome; DBP, diastolic blood pressure; MAP, mean arterial pressure; NA, not available; PP, pulse pressure; SBP, systolic blood pressure.

^aNominal P value.

^bEmpirical P value after correction for multiple testing.